Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 12Recruiting 3Not yet recruiting 3Completed 1Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 12Gastrointestinal 8Tumor-Agnostic 3Head & Neck 3Breast 3Gynecologic 2CNS 2Sarcoma 1Other solid neoplasm 1Endocrine 1

Conditions

Sarcoma 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × anlotinib × Sarcoma × Clear all
NCT05301764 2026-05-20

A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma

Lyvgen Biopharma Holdings Limited

Phase 1/2 Completed
39 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡